Press release
Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Recent FDA Designations and Advancing Clinical Pipeline | DelveInsight
Polycythemia Vera Market Insights
DelveInsight's report, titled "Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034", provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the polycythemia vera treatment landscape over the next decade.
In 2024, the United States dominated the polycythemia vera market, accounting for over 75% of the total market size, which amounts to USD 2 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum polycythemia vera market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.
Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The report also provides historical as well as forecasted polycythemia vera epidemiology segmented by total polycythemia vera prevalent population, prevalent population of polycythemia vera based on symptoms, gender-specific prevalence of polycythemia vera, polycythemia vera prevalence by gene mutation, polycythemia vera prevalence based on risk, and age-specific prevalence of polycythemia vera in the 7MM.
The report estimates that the 7MM had approximately 320,000 polycythemia vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the PV patient share in 7MM is attributed to males, whereas 44% is attributed to females. Additionally, across all races and ethnicities, the polycythemia vera incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.
Discover evolving trends in Polycythemia Vera patient pool forecasts @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Polycythemia vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the polycythemia vera management include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these polycythemia vera therapies.
While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.
The report highlights that the polycythemia vera clinical pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutics), and others.
Unlock which emerging polycythemia vera drug is expected to capture the largest market share in 7MM by 2034. Visit the Polycythemia Vera Market Insights @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
In September 2025, the FDA awarded Breakthrough Therapy Designation to rusfertide for erythrocytosis in polycythemia vera. Furthermore, Rusfertide Phase 3 VERIFY trial results presented at ASCO 2025: These results demonstrated significant efficacy, with 76.9% of rusfertide-treated patients plus standard of care achieving a clinical response versus placebo. The topline results supported regulatory advancement and FDA designation.
In May 2025, Givinostat received FDA fast track status to support expedited review and regulatory support for patients needing innovative Polycythemia Vera therapy.
In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. The detailed results were presented at the ASCO 2025 Annual Meeting Plenary Session in June 2025, demonstrating rusfertide's ability to more than double clinical response rates across high- and low-risk PV groups.
Ionis Pharmaceuticals and Ono Pharmaceutical announced a global license agreement for sapablursen in polycythemia vera in March 2025.
Furthermore, in May 2025, the FDA has granted Fast Track designation to Italfarmaco's givinostat for polycythemia vera treatment, recognizing its potential to address an urgent unmet need in this rare blood cancer. These recent developments indicate positive momentum in the Polycythemia Vera treatment market.
Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.
Related Reports
Polycythemia Vera Pipeline Insight [https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr]
Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine, among others.
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Recent FDA Designations and Advancing Clinical Pipeline | DelveInsight here
News-ID: 4243319 • Views: …
More Releases from DelveInisight Business Research
Triple-Negative Breast Cancer Market Dynamics: Growth Rate, Key Players, Emergin …
The triple-negative breast cancer treatment market is poised for significant expansion, driven by the introduction of novel targeted therapies, immunotherapeutics, and antibody-drug conjugates by key players such as Merck, Roche, Gilead Sciences, AstraZeneca, Daiichi Sankyo, Seagen, Immunomedics, Novartis, BMS, Pfizer, and Eisai, among others. This market growth is further fueled by increasing triple-negative breast cancer incidence rates, improved diagnostic capabilities, and substantial R&D investments addressing the high unmet needs in…
Severe Asthma Market Expected to Grow Significantly Through 2034: DelveInsight | …
Solrikitug, developed initially by Merck & Co. and now advanced by Uniquity Bio with funding from Blackstone Life Sciences, is currently in Phase II clinical development for multiple inflammatory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and eosinophilic esophagitis. The severe asthma market, which is already dominated by major players such as AstraZeneca, Sanofi, Teva, GSK, Regeneron, Amgen, Ellodi, Bristol Myers Squibb, Revolo, EsoCap, and Pfizer, is expected to…
Nonmelanoma Skin Cancer Market Poised for Significant Growth by 2034, Driven by …
The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing disease prevalence, advancements in diagnostic techniques, and the introduction of novel treatment options. As research progresses, new therapies will likely address existing treatment gaps, enhancing patient care and market growth. Leading Nonmelanoma Skin Cancer companies actively advancing research in this landscape include Sensus Healthcare, DUSA Pharmaceuticals Inc., Skin Analytics Limited, Pfizer, Bristol-Myers…
Limbal Stem Cells Deficiency Market Set for Robust Growth Through 2034 | DelveIn …
The limbal stem cells deficiency market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Kala Pharmaceuticals, CLIPS BnC Co., Ltd, RHEACELL GmbH, Holostem Terapie Avanzate, StemSight, Brightstar Therapeutics, and others.
DelveInsight's "Limbal Stem Cells Deficiency - Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the limbal stem cells deficiency treatment market, historical and forecasted…
More Releases for Polycythemia
Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth
Introduction
Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the…
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis.
DelveInsight's "Polycythemia Vera - Pipeline Insight,…
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight.
Polycythemia Overview:
Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period.
The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
